Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007793
Filing Date
2022-05-05
Accepted
2022-05-05 16:01:16
Documents
62
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alrn-20220331.htm   iXBRL 10-Q 1575859
2 EX-31.1 alrn-ex31_1.htm EX-31.1 17017
3 EX-31.2 alrn-ex31_2.htm EX-31.2 16518
4 EX-32.1 alrn-ex32_1.htm EX-32.1 10529
5 EX-32.2 alrn-ex32_2.htm EX-32.2 9005
  Complete submission text file 0000950170-22-007793.txt   6543625

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT alrn-20220331_cal.xml EX-101.CAL 33148
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alrn-20220331.xsd EX-101.SCH 37245
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alrn-20220331_lab.xml EX-101.LAB 369301
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alrn-20220331_pre.xml EX-101.PRE 260731
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT alrn-20220331_def.xml EX-101.DEF 133824
56 EXTRACTED XBRL INSTANCE DOCUMENT alrn-20220331_htm.xml XML 1304521
Mailing Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210
Business Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210 617-995-0900
AILERON THERAPEUTICS INC (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38130 | Film No.: 22896017
SIC: 2834 Pharmaceutical Preparations